Imatinib and prostate cancer: Lessons learned from targeting the platelet-derived growth factor receptor

Aaron Rosenberg, Paul Mathew

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Introduction: The platelet derived growth factor (PDGF) signaling pathway has been implicated in both epithelial and stromal mechanisms of prostate cancer progression and postulated as a target for therapy in bone metastases. Imatinib mesylate is a potent inhibitor of the platelet-derived growth factor receptor (PDGFR) and its activity has been tested in preclinical models and in Phase I and II clinical trials. Areas covered: This review summarizes the preclinical data on PDGF/PDGFR in prostate cancer, and reviews the clinical and correlative data using imatinib as a PDGFR inhibitor. Expert opinion: To date, the use of imatinib to treat men with prostate cancer has been ineffective, and PDGFR inhibition may in fact accelerate advanced forms of the disease and antagonize taxane efficacy. Given the major discordance between preclinical models and clinical experimentation, an accurate understanding of the PDGF-regulated interactions between metastatic prostate cancer and the bone micro-environment is evidently warranted. Correlations of pharmacodynamic monitoring of imatinib-induced PDGFR inhibition with progression-free and overall survival outcomes have led to the hypothesis that PDGF may function as a homeostatic factor in bone metastases. Recent laboratory studies defining PDGFR-regulated pericytes as gatekeepers of metastases may relate to these clinical observations.

Original languageEnglish (US)
Pages (from-to)787-794
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume22
Issue number6
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Platelet-Derived Growth Factor Receptors
Prostatic Neoplasms
Platelet-Derived Growth Factor
Neoplasm Metastasis
Bone and Bones
Bone Neoplasms
Pericytes
Phase II Clinical Trials
Clinical Trials, Phase I
Expert Testimony
Disease-Free Survival
Imatinib Mesylate

Keywords

  • Biomarkers
  • Bone metastases
  • Imatinib
  • Preclinical models
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Imatinib and prostate cancer : Lessons learned from targeting the platelet-derived growth factor receptor. / Rosenberg, Aaron; Mathew, Paul.

In: Expert Opinion on Investigational Drugs, Vol. 22, No. 6, 01.06.2013, p. 787-794.

Research output: Contribution to journalArticle

@article{6c5ff20a9f504e1b92c007335c555e3c,
title = "Imatinib and prostate cancer: Lessons learned from targeting the platelet-derived growth factor receptor",
abstract = "Introduction: The platelet derived growth factor (PDGF) signaling pathway has been implicated in both epithelial and stromal mechanisms of prostate cancer progression and postulated as a target for therapy in bone metastases. Imatinib mesylate is a potent inhibitor of the platelet-derived growth factor receptor (PDGFR) and its activity has been tested in preclinical models and in Phase I and II clinical trials. Areas covered: This review summarizes the preclinical data on PDGF/PDGFR in prostate cancer, and reviews the clinical and correlative data using imatinib as a PDGFR inhibitor. Expert opinion: To date, the use of imatinib to treat men with prostate cancer has been ineffective, and PDGFR inhibition may in fact accelerate advanced forms of the disease and antagonize taxane efficacy. Given the major discordance between preclinical models and clinical experimentation, an accurate understanding of the PDGF-regulated interactions between metastatic prostate cancer and the bone micro-environment is evidently warranted. Correlations of pharmacodynamic monitoring of imatinib-induced PDGFR inhibition with progression-free and overall survival outcomes have led to the hypothesis that PDGF may function as a homeostatic factor in bone metastases. Recent laboratory studies defining PDGFR-regulated pericytes as gatekeepers of metastases may relate to these clinical observations.",
keywords = "Biomarkers, Bone metastases, Imatinib, Preclinical models, Prostate cancer",
author = "Aaron Rosenberg and Paul Mathew",
year = "2013",
month = "6",
day = "1",
doi = "10.1517/13543784.2013.787409",
language = "English (US)",
volume = "22",
pages = "787--794",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Imatinib and prostate cancer

T2 - Lessons learned from targeting the platelet-derived growth factor receptor

AU - Rosenberg, Aaron

AU - Mathew, Paul

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Introduction: The platelet derived growth factor (PDGF) signaling pathway has been implicated in both epithelial and stromal mechanisms of prostate cancer progression and postulated as a target for therapy in bone metastases. Imatinib mesylate is a potent inhibitor of the platelet-derived growth factor receptor (PDGFR) and its activity has been tested in preclinical models and in Phase I and II clinical trials. Areas covered: This review summarizes the preclinical data on PDGF/PDGFR in prostate cancer, and reviews the clinical and correlative data using imatinib as a PDGFR inhibitor. Expert opinion: To date, the use of imatinib to treat men with prostate cancer has been ineffective, and PDGFR inhibition may in fact accelerate advanced forms of the disease and antagonize taxane efficacy. Given the major discordance between preclinical models and clinical experimentation, an accurate understanding of the PDGF-regulated interactions between metastatic prostate cancer and the bone micro-environment is evidently warranted. Correlations of pharmacodynamic monitoring of imatinib-induced PDGFR inhibition with progression-free and overall survival outcomes have led to the hypothesis that PDGF may function as a homeostatic factor in bone metastases. Recent laboratory studies defining PDGFR-regulated pericytes as gatekeepers of metastases may relate to these clinical observations.

AB - Introduction: The platelet derived growth factor (PDGF) signaling pathway has been implicated in both epithelial and stromal mechanisms of prostate cancer progression and postulated as a target for therapy in bone metastases. Imatinib mesylate is a potent inhibitor of the platelet-derived growth factor receptor (PDGFR) and its activity has been tested in preclinical models and in Phase I and II clinical trials. Areas covered: This review summarizes the preclinical data on PDGF/PDGFR in prostate cancer, and reviews the clinical and correlative data using imatinib as a PDGFR inhibitor. Expert opinion: To date, the use of imatinib to treat men with prostate cancer has been ineffective, and PDGFR inhibition may in fact accelerate advanced forms of the disease and antagonize taxane efficacy. Given the major discordance between preclinical models and clinical experimentation, an accurate understanding of the PDGF-regulated interactions between metastatic prostate cancer and the bone micro-environment is evidently warranted. Correlations of pharmacodynamic monitoring of imatinib-induced PDGFR inhibition with progression-free and overall survival outcomes have led to the hypothesis that PDGF may function as a homeostatic factor in bone metastases. Recent laboratory studies defining PDGFR-regulated pericytes as gatekeepers of metastases may relate to these clinical observations.

KW - Biomarkers

KW - Bone metastases

KW - Imatinib

KW - Preclinical models

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84878224514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878224514&partnerID=8YFLogxK

U2 - 10.1517/13543784.2013.787409

DO - 10.1517/13543784.2013.787409

M3 - Article

C2 - 23540855

AN - SCOPUS:84878224514

VL - 22

SP - 787

EP - 794

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -